Related Experiment Video
Updated: Jul 17, 2026

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
Pharmacogenetic analyses in people with dementia in Northeast Germany
Marleen Julia Meyer-Tönnies1, Leefke Schwarz1, Diana Wucherer2
1General Pharmacology Institute of Pharmacology Center of Drug Absorption and Transport (C_DAT) University Medicine Greifswald Greifswald Germany.
Introduction:
Pharmacogenetics-guided prescribing may reduce adverse drug reactions by 30%. European and American expert groups (Dutch Pharmacogenetics Working Group and Clinical Implementation Consortium) issue genotype-based dosage recommendations, but pharmacogenetic testing is still not routinely used. Here, we assess the potential of pharmacogenetic testing to optimize pharmacotherapy in people with dementia (PwD).
Methods:
We genotyped variants in CYP2D6 , CYP2C9, CYP2C19, CYP3A4, CYP3A5, and SLCO1B1 genes and related them to individual medication data in 115 PwD from an epidemiological cohort from Northeast Germany.
Results:
The vast majority of PwD (93%) carried at least one actionable variant. Fourteen (12%) had at least one strongly actionable variant. Four of them (4%) took the drug affected and carried the strongly actionable genetic variant.
Discussion:
Pharmacogenetic testing may contribute to improved pharmacotherapy in PwD. The potential improvements were mainly for medications commonly taken by elderly, but also for medications used to treat or associated with progression of dementia.
Related Concept Videos
Pharmacodynamics in Geriatric Patients: Effects of Age
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenomics: Identification of New Drug Targets
Drug Dosing: Geriatric Patients

